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Abstract Angiogenesis is essential for tumor growth and me-
tastasis. Endocrine gland-derived vascular endothelial growth
factor (EG-VEGF) is an angiogenic factor predominantly
expressed in steroidogenic organs like the adrenal gland, ova-
ry, testes, and placenta. EG-VEGF has antiapoptotic, mitogen-
ic, and chemoattractive properties mediated via the two G
protein-coupled receptors prokineticin receptor 1 (PKR1)
and prokineticin receptor 2 (PKR2). We investigated the ex-
pression of EG-VEGF and its receptors in a large number of
normal adrenal glands (NAG), adrenocortical adenomas
(ACA), and carcinomas (ACC) using real-time PCR (NAG,
n=12; ACA, n=24; and ACC, n=30) and immunohistochem-
istry (NAG, n=9; ACA, n=23; and ACC, n=163) and evalu-
ated its impact on patients’ survival. EG-VEGF, PKR1, and
PKR2 mRNA and protein are expressed in NAG and the vast
majority of ACA and ACC samples. The mean EG-VEGF
mRNA expression was significantly lower in ACC (606.5±
77.1 copies) compared to NAG (4,043±1,111) and cortisol-
producing adenomas (CPA) (4,433±2,378) (p<0.01 and
p<0.05, respectively). However, cytoplasmic and nuclear
EG-VEGF protein expression was either significantly higher
or similar in ACC (H score 2.4±0.05, p<0.05 and 1.7±0.08,
n.s., respectively) compared to NAG (1.8±0.14 and 1.7±0.2).
Nuclear protein expression of either EG-VEGF or PKR1 or
both is predictive for a higher mortality compared to patients
without nuclear expression (hazard ratio (HR)=5.15; 95 %
confidence interval (CI)=1.24–21.36, n=100, p=0.02 inde-
pendent of age, sex, and tumor stage). These findings suggest
that EG-VEGF and its receptor PKR1 might play a role in the
pathogenesis of adrenocortical tumors and could serve as
prognostic markers for this rare malignant disease.
Introduction
Adrenocortical carcinoma (ACC) is a rare and highly malig-
nant tumor whose pathogenesis is largely unclear [11, 13, 15].
Treatment options are limited and, beside surgery in localized
stages, mitotane (adjuvantly or palliatively) or etoposide,
doxorubicin, and cisplatin plus mitotane are the current stan-
dards [2, 14, 56]. Up to now, only a few prognostic markers
are available to guide treatment decisions.
For several decades, it has been established that angiogen-
esis is essential for tumor growth and metastasis. It is impos-
sible for tumors to expand for more than a few millimeters
without neovascularization [21]. Antiangiogenic therapies,
mostly targeting the angiogenic key factor vascular endothe-
lial growth factor (VEGF) or its receptor VEGFR-2, are al-
ready successfully applied in many solid tumors such as
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colorectal carcinoma [26], renal cell carcinoma [40], neuroen-
docrine tumors [48], or thyroid cancer [5, 10, 59]. In 2001, the
endocrine gland-derived VEGF (EG-VEGF) was identified as
the first tissue-specific angiogenic factor predominantly
expressed in steroidogenic organs like the adrenal gland, tes-
tes, ovary, and placenta. Both EG-VEGF and VEGF have a
HIF-1 binding site and are induced by hypoxia. While sharing
mitogenic, permeability enhancing, antiapoptotic, and
chemoattractive properties, VEGF and EG-VEGF do not be-
long to the same gene family [31]. EG-VEGF (also known as
prokineticin 1 or PK1) is a secreted glycoprotein and has
prokinetic effects on gut [33]. EG-VEGF belongs to the AVIT
protein family and shares the amino terminal sequence with
prokineticin 2 (mammalian orthologue of Bombina variegata
peptide 8), which is not expressed in human adrenal tissue
[32]. The two G protein-coupled receptors prokineticin
Table 1 Patients and tumor
characteristics Age (years) Sex (M/F) Tumor size (cm)
Samples used for mRNA expression analysis
ACC (n=30)a 49 (20) 10/18 11.5 (4.0)
ENSAT tumor stage 1 (n=1) 46 0/1 3.0
ENSAT 2 (n=16) 46 (22) 6/10 12.1 (4.0)
ENSAT 3 (n=2) 34 (24) 0/2 12.0 (1.4)
ENSAT 4 (n=9) 59 (12) 4/5 11.4 (3.8)
Endocrine activity (n=23)b
Excess of cortisol (+/− other hormones) (n=18)
Excess of sex hormones and precursors only (n=2)
No hormone excess (n=3)
NAG (n=12) 53 (10) 8/4 –
ACA (n=24) 52 (15) 12/12 3.5 (2.6)
Cortisol-producing adenoma (n=8) 40 (37) 3/5 2.9 (1.9)
Aldosterone-producing adenoma (n=8) 53 (15) 3/5 1.9 (0.8)
Endocrine-inactive adenoma (n=8) 64 (10) 6/2 5.6 (2.7)
For immunohistochemical analysis
ACC (n=163) 49 (16) 59/104 12 (4.5)
Primary tumor (n=130)c 49 (16) 47/83 12 (4.4)
ENSAT tumor stage 1 (n=5) 54 (24) 2/3 4.7 (0.3)
ENSAT 2 (n=48) 48 (17) 19/29 11.9 (4.5)
ENSAT 3 (n=41) 53 (14) 14/27 11.8 (3.6)
ENSAT 4 (n=34) 47 (18) 11/23 13.4 (4.4)
Endocrine activity (n=84)d
Excess of cortisol (+/− other hormones) (n=48)
Excess of sex hormones and precursors only (n=13)
Excess of mineralocorticoids only (n=4)
No hormone excess (n=19)
Local recurrence (n=19) 46 (17) 9/10 10.6 (3.9)
Metastasis (n=14) 42 (11) 3/11 12 (5.9)
NAG (n=9) 62 (16) 2/7 –
ACA (n=23) 53 (15) 7/16 2.3 (0.7)
Cortisol-producing adenoma (n=8) 45 (12) 0/8 2.8 (0.2)
Aldosterone-producing adenoma (n=8) 46 (12) 3/5 1.7 (0.6)
Endocrine-inactive adenoma (n=7) 70 (5) 4/3 2.2 (0.7)
Data are mean (±SD) or numbers
ENSAT European Network for the Study of Adrenal Tumors (www.ensat.org), M male, F female
a In two cases, tumor stage was not determined
bNo information about hormone production available (5×)
c Two patients were lost to follow-up. In two cases, tumor stage was not determined
dNo information about hormone production available (45×)
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receptor 1 (PKR1) and prokineticin receptor 2 (PKR2) repre-
sent cognate receptors for EG-VEGF [36, 38]. EG-VEGF
plays a role in the pathology of endocrine tumors, such as
Leydig-cell-tumors [51], papillary thyroid cancer [47], and
non-endocrine tumors like neuroblastoma [44], prostate can-
cer [46], gastrointestinal tumors [22, 23, 41, 55], pancreatic
ductal adenocarcinoma [27, 39, 49], Merkel cell carcinoma
[30], and multiple myeloma [34]. In bovine adrenal cortex-
derived endothelial cells, EG-VEGF promotes proliferation,
migration, and survival of responsive cells [36].
The adrenal gland is probably the highest vascularized or-
gan in the body [42, 54]. Every adrenocyte is in contact with
fenestrated endothelial cells ensuring sufficient oxygenation
for hormone biosynthesis [57]. The expression of VEGF in
ACC iswell examined [1, 8, 29], but very little is known about
EG-VEGF in adrenocortical tumors. Thus, we aimed to ex-
amine the expression of EG-VEGF, PKR1, and PKR2 in a
large number of ACC, adrenocortical adenomas (ACA), and
normal adrenal glands (NAG) using real-time PCR (NAG, n=
12; ACA, n=24 (cortisol-producing adenoma, n=8;
aldosterone-producing adenoma, n=8; endocrine-inactive ad-
enoma, n=8); and ACC, n=30) and immunohistochemistry
(NAG, n=9; ACA, n=23 (cortisol-producing adenoma, n=
8; aldosterone-producing adenoma, n=8; endocrine-inactive
adenoma, n=7); and ACC, n=163). Moreover, we evaluated
its relationship with clinical data, including the impact on
survival in ACC patients.
Materials and Methods
Clinical Data and Specimen
Tissue samples from NAG, ACA, and ACC were collected as
described before [17]. Diagnosis was made based on clinical,
laboratory, radiological, and pathological results. European
Network for the Study of Adrenal Tumors (ENSAT) tumor
stage (www.ensat.org) was used for the classification of
ACC. Clinical data were collected by the German ACC
Registry (www.nebennierenkarzinom.de) and through the
European Network for the Study of Adrenal Tumors registry
(www.ensat.org). Table 1 displays characteristics of patients
and tumors. Patients gave informed consent for collecting
tissue and clinical data, and the study was approved by the
ethics committee of the University of Wuerzburg (Germany,
board approval number 88/11).
RNA Extraction and Real-Time Quantitative PCR
(qPCR)
RNA was extracted from frozen tumor tissue samples (30
ACC, 24 ACA, and 12 NAG) using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Reverse transcription was carried out using the
iscript TM cDNA Synthesis Kit (Bio-Rad Laboratories
GmbH, Munich, Germany) according to the manufacturer’s
manual. Samples were diluted with aqua dest in a relation of
1:15 before use as a template.
Real-time quantitative PCR was performed in dupli-
cates using the TaqMan Technology. A reaction mix of
20 μl containing distillated water, TaqMan MasterMix
(Applied Biosystems, Darmstadt, Germany), and the
primers/probe mixture in the relation 5:10:1 was added
to 5 μl of cDNA (original RNA concentration, 3.31 ng/
μl). Commercial probes were used (Applied Biosystems,
18s: Hs99999901_s1; EG-VEGF: Hs00951617_m1;
PKR1: Hs00373446_m1; PKR2: Hs00431207_m1). A
dilution series with a known cDNA copy number
allowed absolute quantification of cDNA copy number
for each sample.
Immunohistochemistry in Adrenocortical Tumor Samples
The immunohistochemical stainings were performed on a to-
tal of 195 adrenocortical tissue samples (163 ACC, 23 ACA,
and nine NAG). The adrenal tumor samples were assembled
into three tissue microarrays as described [17, 50]. Immuno-
histochemical detection was performed using an indirect
immunoperoxidase technique following high temperature an-
tigen retrieval in 0.01 M citrate buffer (pH 6.0). As primary
antibodies (Table 2), we used EG-VEGF polyclonal rabbit
antibody, dilution of 1:200, kindly provided by Elly S. W.
Ngan, University of Hong Kong, PKR1 polyclonal rabbit an-
tibody (GPR73A), dilution 1:150, and PKR2 polyclonal rab-
bit antibody (GPR 73 B), dilution 1:150 (both antibodies from
MoBiTec (Molecular Biotechnology), Göttingen, Germany).
Table 2 Used antibodies, source, and dilution
Protein Stained protein Clone/species Source Dilution
EG-VEGF Endocrine gland-derived
vascular endothelial growth factor
Polyclonal rabbit Kindly provided by Elly S. W. Ngan [43];
University of Hong Kong
1:200
PKR1 Prokineticin receptor 1 Polyclonal rabbit MoBiTec, Göttingen, Germany 1:150
PKR2 Prokineticin receptor 2 Polyclonal rabbit MoBiTec, Göttingen, Germany 1:150
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The signal was developed using the DAKO HRP-
System (DAKO, Copenhagen, Denmark) and NovaRed
as substrate according to the manufacturer’s instructions
(Vector Laboratories, Burlingame, USA). Nuclei were
counterstained with hematoxylin. As a negative control,
we employed an unspecific IgG isotype antibody and
adrenal capsule adipose tissue as an internal control,
and as a positive control, we used ovary tissue for
EG-VEGF and prostate tissue for PKR1 and PKR2,
showing specific cytoplasmatic staining in accordance
with www.proteinatlas.org (supplementary Fig. 1). All
tissue array slides were analyzed independently by two
investigators (D.H. and L.K.). Samples were regarded as
evaluable when at least two of five array spots were
intact. Where discrepancies were observed, results were
double checked by both investigators together with a
third observer (S.S.). Cytoplasmic and nuclear staining
intensity was assigned to the categories no staining (0),
weak (1), moderate (2), and strong (3). The percentage
of positive cells was assessed for each specimen and
scored 0 if 0 % were positive, 0.5 if 10–49 %, and 1
if 50 % or more cells were positive. A semiquantitative
H score was calculated by multiplying the staining
intensity score with the percentage of positive cells
score as described [45]. Later on, for survival analysis
purpose, the weak, moderate, and strong stainings were
accumulated into a general positive staining.
Statistical Analysis
Data are presented as mean±standard error of the mean
(SEM). Differences in expression were analyzed using non-
parametric Kruskal-Wallis test and Dunn’s post hoc test. Dif-
ferences in PKR2 mRNA expression were analyzed using
nonparametric Mann-Whitney test. We used a Cox regression
model for overall survival analyses. Overall survival was de-
fined as time elapsed from primary resection of ACC to death
or last follow-up visit. A p value<0.05 was regarded as sig-
nificant. A univariate and an additional multivariate cox re-
gression analysis including age, sex, and ENSAT tumor stage
[12] was carried out. Statistical analyses were performed with
SPSS statistics version 22 (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism (version 6, GraphPad Software Inc., San
Diego, CA, USA).
Results
EG-VEGF, PKR1, and PKR2 mRNA Expression
EG-VEGF mRNA was expressed in all NAG (n=12), ACA
(n=24), and ACC (n=30). Mean mRNA expression was
highest in cortisol-producing adenomas (CPA, 4,433±2,378
Fig. 1 EG-VEGF, PKR1, and PKR2 mRNA expression in adrenal
tissues. EG-VEGF (a), PKR1 (b), and PKR2 (c) mRNA copy number/
16.55 ng RNA is displayed for every sample. Black bars represent means
with SEM. NAG normal adrenal glands, ACC adrenocortical carcinoma,
ACA adrenocortical adenoma divided in cortisol-producing adenoma
(CPA), aldosterone-producing adenoma (APA), and endocrine-inactive
adenoma (EIA). *p<0.05, **p<0.01
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copies/16.55 ng RNA) similar to the expression in NAG (4,
043±1,111 copies). There was a significantly lower mRNA
expression in ACC compared to NAG and CPA (606.5±77
copies, p<0.01 and p<0.05, respectively) using ordinary
one-way ANOVA with Turkey’s multiple comparisons test
(Fig. 1a). The expression of PKR1 and PKR2 mRNA in
NAG, ACA, and ACC was examined on a subset of samples.
PKR1 mRNA could be detected in all five NAG (3,148±2,
842 copies), nine out of ten ACC (227.8±42.93 copies), and
four out of five ACA (two cortisol-producing adenomas, one
aldosterone-producing adenoma, one endocrine-inactive ade-
noma) (2,301±2,110 copies) with the strongest expression in
the aldosterone-producing adenoma (8,630 copies) (Fig. 1b).
PKR2 mRNA was expressed only very weakly (Fig. 1c).
EG-VEGF, PKR1, and PKR2 Protein Expression
Specificity of the antibodies was proven using positive
and negative controls: The EG-VEGF antibody showed
a specific staining on ovary tissue, and the PKR1 and
PKR2 antibodies showed a specific staining on prostate
tissue. Specific staining was detected in the cytoplasm,
not in the nucleus. Employment of an unspecific IgG
isotype antibody prevented positive staining, respective-
ly. Moreover, on adrenal capsule tissue, no specific
staining was detected (supplementary Fig. 1).
The immunohistochemical stainings of NAG, EG-VEGF,
PKR1, and PKR2 revealed that these proteins were predomi-
nantly expressed in the adrenal cortex and only weakly or
Fig. 2 Immunohistochemical staining of normal adrenal glands and
adrenocortical carcinoma against EG-VEGF, PKR1, and PKR2.
Expression of EG-VEGF (first row), PKR1 (second row), and PKR2
(third row) in normal adrenal glands (a, d, g, 1 = adrenal capsule, 2 =
adrenal cortex (a = zona glomerulosa, b = zona fasciculata, c = zona
reticularis), 3=adrenal medulla) and ACC (b, c, e, f, h, i). b Example
for positive nuclear staining. c Example for negative nuclear staining.
Magnification: ×40
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absent in the capsule and medulla. EG-VEGF expression was
highest in the zona glomerulosa, whereas PKR1 and PKR2
proteins were equally detectable in the zona glomerulosa,
zona fasciculata, and zona reticularis. The specific immuno-
staining was detected both in the nucleus and cytoplasm for all
the three investigated proteins (Fig. 2 and Table 3). We there-
fore decided to evaluate the different cell compartments of
each sample. The intra-tumor heterogeneity concerning
cytoplasmatic and nuclear staining was predominantly minor
(approximately 10 %). Hence, staining intensity and H scores
were identical. Ninety-nine percent of the evaluable ACC
showed a positive cytoplasmic staining against EG-VEGF
with 51 % being strong (Table 3). EG-VEGF was also detect-
able in the cytoplasm of all NAG and ACA (Fig. 3a). Nuclear
staining against EG-VEGFwas present in 84% of ACC, 91%
of ACA, and all NAG (Fig. 3b). PKR1 protein was expressed
in the cytoplasm of 95 % of ACC, 89 % of NAG, and 95 % of
ACA (Fig. 3c). Nuclear staining against PKR1, however, was
only observed in 69 % of ACC, 77 % of NAG, and 68 % of
ACA (Fig. 3d). In contrast, PKR2 protein staining was either
negative or weak to moderate in all samples and independent
of subcellular localization (Fig. 3e, f and Table 3). Cytoplas-
mic EG-VEGF expression was significantly higher in ACC
(mean H score 2.4±0.06) compared to NAG (mean H score
1.8±0.14, p<0.05). Apart from this, nuclear EG-VEGF ex-
pression and cytoplasmic and nuclear, PKR1, and PKR2 pro-
tein expression did not differ significantly between ACC,
NAG, and ACA (Fig. 3).
Positive Nuclear Staining Against EG-VEGF and PKR1 Is
Predictive for a Higher Mortality
We performed overall survival analyses using Cox regression
plots only in ACC samples coming from primary tumors with
available immunostaining and clinical data (for multivariate
analysis: EG-VEGF n=110, PKR1 n=101, PKR2 n=115)
(Fig. 4 and Table 4). Cytoplasmic EG-VEGF, PKR1, and
PKR2 expression did not correlate with overall survival. How-
ever, a positive nuclear staining against EG-VEGF was associ-
ated with a significantly higher mortality in patients with ACC
(hazard ratio (HR) for death 2.78; 95% confidence interval (CI)
1.27–6.08; p=0.01) (Fig. 4a). Similarly, patients with a positive
Table 3 Cytoplasmic and nuclear immunohistochemical staining intensity of ACC, adrenal adenomas, and normal adrenal glands against EG-VEGF,
PKR1, and PKR2
Staining intensity Negative Weak Moderate Strong
EG-VEGF cytoplasm
ACC (n=146) 1 (0.7 %) 14 (9.6 %) 56 (38.4 %) 75 (51.4 %)
Adenoma (n=23) 0 5 (21.7 %) 12 (52.2 %) 6 (26.1 %)
NAG (n=9) 0 2 (22.2 %) 7 (77.8 %) 0
EG-VEGF nucleus
ACC (n=146) 24 (16.4 %) 35 (24.0 %) 55 (37.7 %) 32 (21.9 %)
Adenoma (n=23) 2 (8.7 %) 6 (26.1 %) 10 (43.5 %) 5 (21.7 %)
NAG (n=9) 0 4 (44.4 %) 4 (44.4 %) 1 (11.1 %)
PKR1 cytoplasm
ACC (n=137) 7 (5.1 %) 27 (19.7 %) 55 (40.1 %) 48 (35.0 %)
Adenoma (n=22) 1 (4.5 %) 6 (27.3 %) 10 (45.4 %) 5 (22.7 %)
NAG (n=9) 1 (11.1 %) 2 (22.2 %) 5 (55.6 %) 1 (11.1 %)
PKR1 nucleus
ACC (n=137) 42 (30.7 %) 38 (27.7 %) 47 (34.3 %) 10 (7.3 %)
Adenoma (n=22) 7 (31.8 %) 5 (22.7 %) 7 (31.8 %) 3 (13.6 %)
NAG (n=9) 2 (22.2 %) 2 (22.2 %) 5 (55.6 %) 0
PKR2 cytoplasm
ACC (n=153) 29 (19.0 %) 94 (61.4 %) 30 (19.6 %) 0
Adenoma (n=23) 2 (8.7 %) 16 (69.6 %) 5 (21.7 %) 0
NAG (n=9) 1 (11.1 %) 7 (77.8 %) 1 (11.1 %) 0
PKR2 nucleus
ACC (n=153) 94 (61.4 %) 56 (36.6 %) 3 (2.0 %) 0
Adenoma (n=23) 11 (47.8 %) 11 (47.8 %) 1 (4.3 %) 0
NAG (n=9) 5 (55.6 %) 4 (44.4 %) 0 0
Percentages are given in brackets, rounded decimals
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nuclear staining against PKR1 were more likely to die com-
pared to patients with a negative nuclear expression of PKR1
(HR 2.22; 95 % CI 1.23–4.03; p<0.01) (Fig. 4b). The prognos-
tic value was even higher when either EG-VEGF or PKR1
protein or both were expressed in the nucleus of ACC cells
compared to patients with none of these factors in the nucleus
(HR 5.65; 95 % CI 1.38–23.12; p=0.02) (Fig. 4c). Multivariate
regression analysis including age, sex, and ENSAT tumor stage
confirmed the independent prognostic value of this combina-
tion (EG-VEGF: HR 2.41, 95 % CI 1.08–5.38, p=0.03; PKR1:
HR 1.95, 95 % CI 1.06–3.56, p=0.03; EG-VEGF or PKR1:
HR 5.15, 95 % CI 1.24–21.36, p=0.02) (Table 4). Excess of
cortisol production did not influence survival in our patients
(HR 1.06, CI 0.63–1.76, p=0.84) (supplementary Fig. 2).
Fig. 3 H score distribution of EG-VEGF, PKR1, and PKR2
immunohistochemical staining of normal and tumoral adrenocortical
tissues. Summary of differential cytoplasmic (a, c, and e) and nuclear
(b, d, and f) EG-VEGF (a and b), PKR1 (c and d), and PKR2 (e and f)
staining intensity (H score) in normal adrenal glands (NAG),
adrenocortical adenomas (ACA), and adrenocortical carcinomas (ACC)
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Discussion
The key finding of our study is the strong prognostic po-
tential of nuclear staining of EG-VEGF and its receptor
PKR1 for patient outcome in ACC. In general, EG-VEGF
and both of its receptors PKR1 and PKR2 are present in
most adrenocortical adenomas and carcinomas. However,
only the nuclear localization harbors prognostic value. In-
deed, we are the first to describe nuclear expression of the
glycoprotein EG-VEGF and its G protein-coupled receptors
PKR1 and PKR2. The specificity of our antibodies was
proven on negative controls and positive controls in accor-
dance with www.proteinatlas.org and previous publications
on the expression of EG-VEGF in ovary tissue [18, 20] and
PKR1 and PKR2 in prostate tissue [46]. The normal
tissues showed in contrast to tumor tissues no nuclear stain-
ing. Over the last years, knowledge about intracellular pro-
tein transport has increased. It has been shown that subcel-
lular trafficking of proteins to the Bwrong^ cell compart-
ment, such as the nucleus for a membrane receptor, can
result in disease like cancer by loss of function or gain of
activity in the Bwrong^ cell compartment. Such nuclear
misleading of proteins is known for epidermal growth fac-
tor receptor (EGFR) [4], FGF [37], and VEGF receptor
[16]. Concerning EG-VEGF, this nuclear expression might
represent active interaction of both ligand and receptor re-
quired for relevant influence on cell cycle and transcription.
Remarkably, the EG-VEGF promotor has a potential bind-
ing site for an orphan nuclear receptor essential for adrenal
development, steroidogenic-factor 1 (SF)-1, or NR5A1
[32]. In neuroblastoma cells, bovine adrenal cortex capil-
lary endothelial cells and bovine glomerulosa and
fasciculata cells, an autocrine proliferation mechanism of
EG-VEGF, probably via its receptor PKR1, could be dem-
onstrated [28, 35, 44]. Thus, we hypothesize that there ex-
ists a similar mechanism in tumor growth in ACC. Of note,
if either EG-VEGF or PKR1 or both of them are present in
the nucleus, the likelihood that patients die from ACC is
more than five times higher than if none of these factors are
detectable. Interestingly, this result is exactly confirmed in
multivariate analysis.
Up to now, only the tumor stage is generally accepted as a
prognostic tool. However, within a given tumor stage, survival
of ACC patients is quite heterogeneous [25] resulting in un-
certainty of clinicians regarding aggressiveness of treatment
Fig. 4 Univariate Cox regression survival curves based on nuclear
expression of EG-VEGF and PKR1. a Survival of 112 patients with
ACC depending on nuclear expression of EG-VEGF: negative nuclear
EG-VEGF expression (grey) and positive (black). b Survival of 103
patients with ACC depending on nuclear expression of PKR1: negative
nuclear PKR1 expression (grey) and positive (black). c Survival of 102
patients with ACC depending on nuclear expression of EG-VEGF and
PKR1: both negative (grey) and both or at least one positive (black)
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when confronted with an individual patient. Therefore, reli-
able prognostic markers are urgently needed. In the last years,
few immunohistochemical markers with prognostic potential
have been suggested [3, 9, 17, 52, 53, 58]. In addition to these
markers, nuclear staining of EG-VEGF and its receptor PKR1
is interesting owing to its high prognostic value.
Table 4 Factors influencing
overall survival in patients with
ACC according to univariate and
multivariate analysis
Variables Univariate analysis Multivariate analysisa
HR 95 % CI p HR 95 % CI p
Age
Younger than median (n=64)b
Older than median (n=64) 1.34 0.88–2.05 0.18 1.38 0.89–2.13 0.15
Sex
Male (n=46)c
Female (n=82) 0.95 0.62–1.48 0.83 0.84 0.53–1.31 0.43
ENSAT tumor stage
I–II (n=53)d
III (n=39) 1.79 1.05–3.06 0.03 1.78 1.04–3.06 0.04
IV (n=34) 4.14 2.39–7.19 <0.001 4.25 2.44–7.41 <0.001
EG-VEGF cytoplasm
Negative + weak (n=9)e
Moderate + strong (n=103) 2.59 0.82–8.25 0.11 2.00 0.60–6.33 0.27
EG-VEGF nucleus
Negative (n=18)d
Positive (n=94) 2.78 1.27–6.08 0.01 2.41 1.08–5.38 0.03
PKR1 cytoplasm
Negative (n=5)d
Positive (n=98) 1.71 0.54–5.46 0.37 2.33 0.71–7.66 0.16
PKR1 nucleus
Negative (n=30)d
Positive (n=73) 2.22 1.22–4.03 0.01 1.95 1.06–3.56 0.03
PKR2 cytoplasm
Negative (n=19)d
Positive (n=98) 1.57 0.83–2.97 0.17 1.58 0.82–3.04 0.17
PKR2 nucleus
Negative (n=69)d
Positive (n=48) 1.13 0.72–1.78 0.59 1.33 0.84–2.13 0.23
EG-VEGF and PKR1 nucleus
Both negative (n=10)d
Both or at least one positive (n=92) 5.65 1.38–23.12 0.02 5.15 1.24–21.36 0.02
Only primary tumor samples were used for this survival analysis. Two patients were lost to follow-up. Samples
were not evaluable, if less than two of five spots were intact (EG-VEGF array, 16; PKR1 array, 25; PKR2 array,
11). Therefore, the number of samples is slightly different from Tables 1 and 3
HR hazard ratio, 95 % CI 95 % confidence interval
a The multivariate analysis included age, sex, and tumor stage (three groups, owing to the low number of patients
with ENSAT tumor stage 1, these were combined with patients with ENSAT tumor stage 2 into one group) as
covariates. In two cases, tumor stage was not determined
bYounger age than the median was taken as the reference category
cMale sex was the reference category
d ENSAT stage I and II was the reference category
e Since cytoplasmic staining against EG-VEGF was negative in only one probe, negative and weak staining were
combined as the reference category
dNegative staining was the reference category
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To our knowledge, this is the first report of the expression
of EG-VEGF and its receptors PKR1 and PKR2 in a large
number of NAG, ACA, and ACC. In our small mRNA study,
EG-VEGF mRNA expression was significantly higher in
NAG compared to ACC. Conversely, cytoplasmic EG-
VEGF protein expression was significantly higher in ACC
compared to NAG. There are multiple reasons for this discrep-
ancy in mRNA and protein expression: Apart from the possi-
ble inaccuracy of technical methods and low sample size (only
eight patients were identical in mRNA and protein analysis),
mRNA expression does not always predict protein expression,
especially in genes involved in development and regulation.
Alternative splicing, translational modifications, and different
degradation of mRNA and protein all have an impact on
mRNA and protein quantities [24]. Besides the significant
different EG-VEGF mRNA and cytoplasmic expression in
ACC and NAG, the mRNA and protein expression of EG-
VEGF, PKR1, and PKR2 did not show any significant differ-
ences between the adrenal entities. A possible explanation
might be the existing strong vascularization of the normal
adrenal gland as an endocrine organ [57], which is still present
in adrenocortical tumors, although the vascular density in
ACC is relatively lower than in NAG andACA [1].Moreover,
angiogenesis is a highly complex process requiring the precise
coordination of many angiogenic factors. Physiologic and
pathologic angiogenesis are still not fully understood [6, 7,
19]. It is conceivable that the angiogenic factors EG-VEGF
and VEGF interact in the adrenal gland as assumed by Thom-
as et al. [57].
The expression pattern of EG-VEGF, PKR1, and PKR2
protein in the adrenal cortex of NAG was different in human
tissue compared to previous examinations by Keramidas et al.
on bovine adrenal cortex tissue [28]. Both in human and bo-
vine tissues, EG-VEGF, PKR1, and PKR2 were predominant-
ly detectable in the cortex with only very weak, respectively,
no, specific staining in the medulla or adrenal capsule. EG-
VEGF expression was highest in the zona glomerulosa in
human tissue, whereas EG-VEGF staining was slightly stron-
ger in the zona fasciculata/reticularis in bovine tissue. PKR1
and PKR2 expression also differed among the two species
with regard to a stronger expression of PKR2 in the bovine
zona glomerulosa. A different expression pattern between the
two species is in accordance with a previous study indicating a
different expression of EG-VEGF amongmammalian species,
probably due to divergence in the promoter sequence [32].
Furthermore, EG-VEGF would be an interesting target for
antiangiogenic therapies against ACC or tumors of the ovary
and testes. In contrast to widespread VEGF, against which
antiangiogenic therapies have already been successfully
established, EG-VEGF is predominantly expressed in ste-
roidogenic organs. Therefore, fewer side effects would be ex-
pected in anti-EG-VEGF therapies in comparison to anti-
VEGF therapies. However, anti-EG-VEGF therapies might
possibly cause gastrointestinal side effects given its prokinetic
effect on gastrointestinal small muscle.
In summary, our work suggests an implication of EG-
VEGF and its receptor PKR1 in pathogenesis of ACC. How-
ever, the most important finding is that nuclear staining of EG-
VEGF together with PKR1 is one of the best prognostic
markers for overall survival in patients with ACC.
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